Skip to main content
SpringerLink
Log in

Volumetric changes and clinical trajectories in Parkinson’s disease: a prospective multicentric study

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Background

Longitudinal measures of structural brain changes using MRI in relation to clinical features and progression patterns in PD have been assessed in previous studies, but few were conducted in well-defined and large cohorts, including prospective clinical assessments of both motor and non-motor symptoms.

Objective

We aimed to identify brain volumetric changes characterizing PD patients, and determine whether regional brain volumetric characteristics at baseline can predict motor, psycho-behavioral and cognitive evolution at one year in a prospective cohort of PD patients.

Methods

In this multicentric 1 year longitudinal study, PD patients and healthy controls from the MPI-R2* cohort were assessed for demographical, clinical and brain volumetric characteristics. Distinct subgroups of PD patients according to motor, cognitive and psycho-behavioral evolution were identified at the end of follow-up.

Results

One hundred and fifty PD patients and 73 control subjects were included in our analysis. Over one year, there was no significant difference in volume variations between PD and control subjects, regardless of the brain region considered. However, we observed a reduction in posterior cingulate cortex volume at baseline in PD patients with motor deterioration at one year (p = 0.017). We also observed a bilateral reduction of the volume of the amygdala (p = 0.015 and p = 0.041) and hippocampus (p = 0.015 and p = 0.053) at baseline in patients with psycho-behavioral deterioration, regardless of age, dopaminergic treatment and center.

Conclusion

Brain volumetric characteristics at baseline may predict clinical trajectories at 1 year in PD as posterior cingulate cortex atrophy was associated with motor decline, while amygdala and hippocampus atrophy were associated with psycho-behavioral decline.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49:328–338. https://doi.org/10.1111/ejn.14094

    Article  PubMed  Google Scholar 

  2. Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5:355–363. https://doi.org/10.1016/S1474-4422(06)70411-2

    Article  CAS  PubMed  Google Scholar 

  3. Yang J, Burciu RG, Vaillancourt DE (2018) Longitudinal Progression Markers of Parkinson’s Disease: Current View on Structural Imaging. Curr Neurol Neurosci Rep 18:83. https://doi.org/10.1007/s11910-018-0894-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. McGhee DJ, Royle PL, Thompson PA, Wright DE, Zajicek JP, Counsell CE (2013) A systematic review of biomarkers for disease progression in Parkinson’s disease. BMC Neurol 13:35. https://doi.org/10.1186/1471-2377-13-35

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sarasso E, Agosta F, Piramide N, Filippi M (2021) Progression of grey and white matter brain damage in Parkinson’s disease: a critical review of structural MRI literature. J Neurol 268:3144–3179. https://doi.org/10.1007/s00415-020-09863-8

    Article  PubMed  Google Scholar 

  6. Filippi M, Sarasso E, Piramide N, Stojkovic T, Stankovic I, Basaia S, Fontana A, Tomic A, Markovic V, Stefanova E, Kostic VS, Agosta F (2020) Progressive brain atrophy and clinical evolution in Parkinson’s disease. Neuroimage Clin 28:102374. https://doi.org/10.1016/j.nicl.2020.102374

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn DJ, O’Brien JT (2015) Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain 138:2974–2986. https://doi.org/10.1093/brain/awv211

    Article  PubMed  PubMed Central  Google Scholar 

  8. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x

    Article  PubMed  Google Scholar 

  9. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 55:181–184

    Article  CAS  Google Scholar 

  10. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord 22:41–47. https://doi.org/10.1002/mds.21198

    Article  PubMed  Google Scholar 

  11. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442

    Article  CAS  PubMed  Google Scholar 

  12. Schwab RS, England AC (1969) Projection techniques for evaluating surgery in Parkinson’s Disease. E. & S. Livingstone Ltd., Edinburgh

    Google Scholar 

  13. Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe WH, Stocchi F, Tolosa E (2009) Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov Disord 24:655–661. https://doi.org/10.1002/mds.21745

    Article  PubMed  Google Scholar 

  14. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62. https://doi.org/10.1136/jnnp.23.1.56

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Thompson E (2015) Hamilton Rating Scale for Anxiety (HAM-A). Occup Med (Lond) 65:601. https://doi.org/10.1093/occmed/kqv054

    Article  PubMed  Google Scholar 

  16. Sockeel P, Dujardin K, Devos D, Denève C, Destée A, Defebvre L (2006) The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 77:579–584. https://doi.org/10.1136/jnnp.2005.075929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M, Ardouin C, Chéreau I, Brefel-Courbon C, Ory-Magne F, Klinger H, Peyrol F, Schupbach M, Dujardin K, Tison F, Houeto JL, Krack P, Durif F (2015) International validation of a behavioral scale in Parkinson’s disease without dementia. Mov Disord 30:705–713. https://doi.org/10.1002/mds.26223

    Article  PubMed  Google Scholar 

  18. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ (2010) The clinically important difference on the unified Parkinson’s disease rating scale. Arch Neurol 67:64–70. https://doi.org/10.1001/archneurol.2009.295

    Article  PubMed  Google Scholar 

  19. Lhommée E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, Hälbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-Döring F, Kupsch A, Krüger R, Elben S, Chabardès S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis J-M, Maltête D, Sauvaget A, Rau J, Schnitzler A, Schüpbach M, Schade-Brittinger C, Deuschl G, Houeto J-L, Krack P, Negovanska V, Welter M-L, Corvol J-C, Agid Y, Navarro S, Meier N, Hartmann A, Hesekamp H, Cornu P, Möller B, Nebel A, Raethjen J, Knudsen K, Volkmann J, Falk D, Paschen S, Meister I, Kuhn J, Donner K, Kessler J, Barbe M, Fink G, Maarouf M, Kühn A, Müller B, Faust K, Gruber D, Schneider G-H, Seigneuret E, Pollak P, Fraix V, Kistner A, Rascol O, Arbus C, Danet L, Chaynes P, Groiss SJ, Hartmann C, Südmeyer M, Partowinia-Peters M, Vesper J, Ledily S, Damier P, Raoul S, Trenkwalder C, Richter-Dreske W, Wächter T, Weiss D, Eusebio A, Azulay JP, Polo G, Pinto S, Levin J, Dornier S, Pene F, Hourton D, Quintin M, Hoffart-Jourdain C, Brocvielle H, Balthasar K, Stein M, Harnisch S, Reuss A, Aminossadati B, Nasemann C, Oertel W, Bataille B, Hellwig D, Gharabaghi A, Amtage F, Mertens P, Kloss M, Post B, Speelman H (2018) Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol 17:223–231. https://doi.org/10.1016/S1474-4422(18)30035-8

    Article  PubMed  Google Scholar 

  20. Li A, Yue L, Xiao S, Liu M (2022) Cognitive Function Assessment and Prediction for Subjective Cognitive Decline and Mild Cognitive Impairment. Brain Imaging Behav 16:645–658. https://doi.org/10.1007/s11682-021-00545-1

    Article  PubMed  Google Scholar 

  21. Bender R, Lange S (2001) Adjusting for multiple testing–when and how? J Clin Epidemiol 54:343–349. https://doi.org/10.1016/s0895-4356(00)00314-0

    Article  CAS  PubMed  Google Scholar 

  22. Feise RJ (2002) Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2:8

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ibarretxe-Bilbao N, Junque C, Segura B, Baggio HC, Marti MJ, Valldeoriola F, Bargallo N, Tolosa E (2012) Progression of cortical thinning in early Parkinson’s disease: Cortical Thinning in Early PD. Mov Disord 27:1746–1753. https://doi.org/10.1002/mds.25240

    Article  PubMed  Google Scholar 

  24. Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Trautmann E, Zetterberg H, Taylor P, Friede T, Trenkwalder C (2016) Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 87:168–177. https://doi.org/10.1212/WNL.0000000000002651

    Article  PubMed  PubMed Central  Google Scholar 

  25. Jia X, Liang P, Li Y, Shi L, Wang D, Li K (2015) Longitudinal Study of Gray Matter Changes in Parkinson Disease. AJNR Am J Neuroradiol 36:2219–2226. https://doi.org/10.3174/ajnr.A4447

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Melzer TR, Myall DJ, MacAskill MR, Pitcher TL, Livingston L, Watts R, Keenan RJ, Dalrymple-Alford JC, Anderson TJ (2015) Tracking Parkinson’s Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate Disease. PLoS ONE. 10:e0143923. https://doi.org/10.1371/journal.pone.0143923

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Blair JC, Barrett MJ, Patrie J, Flanigan JL, Sperling SA, Elias WJ, Druzgal TJ (2019) Brain MRI Reveals Ascending Atrophy in Parkinson’s Disease Across Severity. Front Neurol 10:1329. https://doi.org/10.3389/fneur.2019.01329

    Article  PubMed  PubMed Central  Google Scholar 

  28. Oh BH, Moon HC, Kim A, Kim HJ, Cheong CJ, Park YS (2021) Prefrontal and hippocampal atrophy using 7-tesla magnetic resonance imaging in patients with Parkinson’s disease. Acta Radiol Open 10:2058460120988097. https://doi.org/10.1177/2058460120988097

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ramírez-Ruiz B, Martí MJ, Tolosa E, Bartrés-Faz D, Summerfield Ch, Salgado-Pineda P, Gómez-Ansón B, Junqué C (2005) Longitudinal evaluation of cerebral morphological changes in Parkinson’s disease with and without dementia. J Neurol 252:1345–1352. https://doi.org/10.1007/s00415-005-0864-2

    Article  PubMed  Google Scholar 

  30. Benarroch EE (2015) The amygdala: Functional organization and involvement in neurologic disorders. Neurology 84:313–324. https://doi.org/10.1212/WNL.0000000000001171

    Article  PubMed  Google Scholar 

  31. Ibarretxe-Bilbao N, Ramírez-Ruiz B, Tolosa E, Martí MJ, Valldeoriola F, Bargalló N, Junqué C (2008) Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia. J Neurol 255:1324–1331. https://doi.org/10.1007/s00415-008-0885-8

    Article  PubMed  Google Scholar 

  32. Carey G, Görmezoğlu M, de Jong JJA, Hofman PAM, Backes WH, Dujardin K, Leentjens AFG (2021) Neuroimaging of Anxiety in Parkinson’s Disease: A Systematic Review. Mov Disord 36:327–339. https://doi.org/10.1002/mds.28404

    Article  PubMed  Google Scholar 

  33. Thobois S, Prange S, Sgambato-Faure V, Tremblay L, Broussolle E (2017) Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment. Curr Neurol Neurosci Rep 17:76. https://doi.org/10.1007/s11910-017-0788-0

    Article  PubMed  Google Scholar 

  34. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, Dalrymple-Alford JC, Anderson TJ (2012) Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatry 83:188–194. https://doi.org/10.1136/jnnp-2011-300828

    Article  PubMed  Google Scholar 

  35. Kamagata K, Motoi Y, Hori M, Suzuki M, Nakanishi A, Shimoji K, Kyougoku S, Kuwatsuru R, Sasai K, Abe O, Mizuno Y, Aoki S, Hattori N (2011) Posterior hypoperfusion in Parkinson’s disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging 33:803–807. https://doi.org/10.1002/jmri.22515

    Article  PubMed  Google Scholar 

  36. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, Suzuki K, Itoyama Y, Takahashi S, Fukuda H, Mori E (2009) Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord 24:854–862. https://doi.org/10.1002/mds.22444

    Article  PubMed  Google Scholar 

  37. Vogt BA (2019) Cingulate cortex in Parkinson’s disease. Handb Clin Neurol 166:253–266. https://doi.org/10.1016/B978-0-444-64196-0.00013-3

    Article  PubMed  Google Scholar 

  38. de Schipper LJ, van der Grond J, Marinus J, Henselmans JML, van Hilten JJ (2017) Loss of integrity and atrophy in cingulate structural covariance networks in Parkinson’s disease. NeuroImage 15:587–593. https://doi.org/10.1016/j.nicl.2017.05.012

    Article  PubMed  PubMed Central  Google Scholar 

  39. Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, Goetz CG (2014) Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson’s disease with hallucinations. Brain. 137:849–859. https://doi.org/10.1093/brain/awt360

    Article  PubMed  PubMed Central  Google Scholar 

  40. Vercruysse S, Leunissen I, Vervoort G, Vandenberghe W, Swinnen S, Nieuwboer A (2015) Microstructural changes in white matter associated with freezing of gait in Parkinson’s disease: FOg-Related White Matter Changes. Mov Disord 30:567–576. https://doi.org/10.1002/mds.26130

    Article  PubMed  Google Scholar 

  41. Evers LJW, Krijthe JH, Meinders MJ, Bloem BR, Heskes TM (2019) Measuring Parkinson’s disease over time: the real-world within-subject reliability of the MDS-UPDRS. Mov Disord 34:1480–1487. https://doi.org/10.1002/mds.27790

    Article  PubMed  PubMed Central  Google Scholar 

  42. Aleksovski D, Miljkovic D, Bravi D, Antonini A (2018) Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci 39:1971–1976. https://doi.org/10.1007/s10072-018-3522-z

    Article  PubMed  Google Scholar 

  43. Lessig S, Nie D, Xu R, Corey-Bloom J (2012) Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord 27:1125–1128. https://doi.org/10.1002/mds.25070

    Article  PubMed  Google Scholar 

  44. Makarious MB, Leonard HL, Vitale D, Iwaki H, Sargent L, Dadu A, Violich I, Hutchins E, Saffo D, Bandres-Ciga S, Kim JJ, Song Y, Maleknia M, Bookman M, Nojopranoto W, Campbell RH, Hashemi SH, Botia JA, Carter JF, Craig DW, Van Keuren-Jensen K, Morris HR, Hardy JA, Blauwendraat C, Singleton AB, Faghri F, Nalls MA (2022) Multi-modality machine learning predicting Parkinson’s disease. NPJ Parkinsons Dis 8:35. https://doi.org/10.1038/s41531-022-00288-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

France Parkinson Association, Federation for Brain Research, Neuroscience-Parkinson network, call for tenders for the interregional clinical research hospital program.

Author information

Authors and Affiliations

  1. University Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France

    Ana Marques, Elise Macias, Elodie Durand, Carine Chassain, Tiphaine Vidal, Maria Livia Fantini & Franck Durif

  2. Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand University Hospital, Clermont-Ferrand, France

    Ana Marques, Elise Macias, Elodie Durand, Carine Chassain, Tiphaine Vidal, Maria Livia Fantini & Franck Durif

  3. Clermont-Ferrand University Hospital, Biostatistics Unit (DRCI), Clermont-Ferrand, France

    Bruno Pereira

  4. Department of Movement Disorder and NS-PARK/FCRIN Network, Inserm 1172, University of Lille, Lille, France

    Luc Defebvre & Nicolas Carriere

  5. Université Grenoble Alpes, CHU de Grenoble, Service de Neurologie, Grenoble Institute of Neuroscience, and NS-PARK/FCRIN Network, Grenoble, France

    Valerie Fraix & Elena Moro

  6. CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, Lyon, France

    Stéphane Thobois & Elise Metereau

  7. Université Claude Bernard, Lyon I, Lyon, France

    Stéphane Thobois & Elise Metereau

  8. Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C and NS-PARK/FCRIN Network, Lyon, France

    Stéphane Thobois & Elise Metereau

  9. Département de Neurologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France

    Graziella Mangone, Marie Vidailhet & Jean-Christophe Corvol

  10. Department of Neuroradiology, Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France

    Nicolas Menjot de Champfleur

  11. I2FH, Institut d’Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac, CHRU de Montpellier, Montpellier, France

    Nicolas Menjot de Champfleur

  12. Department of Geriatrics and NS-PARK/FCRIN Network, Montpellier University Hospital, Montpellier University, Montpellier, France

    Christian Geny

  13. Service de Neurologie-Maladies Neurodégénératives and NS-PARK/FCRIN Network, CHU Bordeaux, 33000, Bordeaux, France

    Umberto Spampinato & Wassilios G. Meissner

  14. INCIA-UMR 5287, Team P3TN, CNRS/Université de Bordeaux, Bordeaux, France

    Umberto Spampinato

  15. Univ. Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, 33000, Bordeaux, France

    Wassilios G. Meissner

  16. Dept. Medicine, University of Otago, Christchurch, New Zealand

    Wassilios G. Meissner

  17. Department of Neurology and NS-PARK/FCRIN Network, Nancy University Hospital Center, Nancy, France

    Solène Frismand

  18. Department of Neuroradiology, Nancy University Hospital Center, Nancy, France

    Emmanuelle Schmitt

  19. Department of Neurology and NS-PARK/FCRIN Network, Hôpital Maison Blanche, Reims, France

    Anne Doé de Maindreville

  20. Department of Radiology, Hôpital Maison Blanche, Reims, France

    Christophe Portefaix

  21. CReSTIC Laboratory, University of Reims Champagne-Ardenne, Reims, France

    Christophe Portefaix

  22. Centre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor; AP-HP et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé, Université Paris-Est Créteil et Ecole Normale Supérieure Paris Sorbonne Université, Créteil, France

    Philippe Remy & Gilles Fénelon

  23. INSERM, CHU de Poitiers, Université de Poitiers, Centre d’Investigation Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, Poitiers, France

    Jean Luc Houeto

  24. INSERM, CHU de Poitiers, Université de Poitiers, Centre d’Investigation Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, CH Brive la Gaillarde, Poitiers, France

    Olivier Colin

  25. Centre Expert Parkinson, Départements de Pharmacologie Clinique et Neurosciences, Centre d’Investigation Clinique CIC 1436, UMR 1214 TONIC, NeuroToul and NS-PARK/FCRIN Network, INSERM, CHU de Toulouse et Université de Toulouse3, Toulouse, France

    Olivier Rascol

  26. ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, INSERM, UPS, Toulouse, France

    Patrice Peran

  27. INRAE, UR QuaPA, 63122, Saint-Genès-Champanelle, France

    Jean-Marie Bonny

  28. Nuclear Magnetic Resonance Facility for Agronomy, Food and Health, AgroResonance, INRAE, 2018, Saint-Genès-Champanelle, France

    Jean-Marie Bonny

  29. Département de Neuroradiologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225; Hôpital Pitié-Salpêtrière, Paris, France

    Stéphane Lehéricy

  30. Neurology Department, Parkinson Expert Center, CHRU Gabriel Montpied, 63000, Clermont-Ferrand, France

    Ana Marques

  31. New Zealand Brain Research Institute, Christchurch, New Zealand

    Wassilios G. Meissner

  32. CHU-Centre Expert Parkinson de Limoges, Limoges, France

    Jean Luc Houeto

Authors
  1. Ana Marques
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elise Macias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruno Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elodie Durand
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carine Chassain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tiphaine Vidal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luc Defebvre
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nicolas Carriere
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Valerie Fraix
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Elena Moro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Stéphane Thobois
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Elise Metereau
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Graziella Mangone
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Marie Vidailhet
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jean-Christophe Corvol
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Stéphane Lehéricy
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Nicolas Menjot de Champfleur
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Christian Geny
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Umberto Spampinato
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Wassilios G. Meissner
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Solène Frismand
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Emmanuelle Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Anne Doé de Maindreville
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Christophe Portefaix
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Philippe Remy
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Gilles Fénelon
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Jean Luc Houeto
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Olivier Colin
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Olivier Rascol
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Patrice Peran
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Jean-Marie Bonny
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Maria Livia Fantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. Franck Durif
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The R2* Study Group

Corresponding author

Correspondence to Ana Marques.

Ethics declarations

Conflicts of interest

The authors have no relevant financial or non-financial interests to disclose. The authors have no competing interests to declare that are relevant to the content of this article.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 17 KB)

415_2023_11947_MOESM2_ESM.pdf

Supplementary file2 Box plots representation of posterior cingulate cortex volumes in parkinsonian patients with motor impairment vs parkinsonian patients without motor impairment. Considering univariate analysis, effect-size for PCC volumes in PD with motor impairment vs PD without motor impairment using box plots was moderate (− 0.41 [− 0.77; − 0.06]) according to Cohen who has defined effect size bounds as small (ES = 0.2), medium (ES = 0.5), and large (ES = 0.8) (PDF 216 KB)

415_2023_11947_MOESM3_ESM.pdf

Supplementary file3 Univariate results concerning relations between clinical and volumetric changes between V1 and V2, for PD patients: the heatmap represents correlation coefficients intensity (Pearson or Spearman according to statistical distribution. LARS = Lille Apathy Rating Scale; HAM-D = Hamilton Depression scale; HAM-A = Hamilton Anxiety scale; MoCA = Montreal Cognitive Assessment; FOG-Q = Freezing Of Gate Questionnaire; ASBPD = Ardouin Scale of Behavior in Parkinson’s Disease; MDS-UPDRS = Movement Disorder’s Society Unified Parkinson's Disease Rating Scale; LEDD = Levodopa Equivalent Daily Dose; H&Y = Hoehn & Yahr scale. L = left; R = Right. White = No correlation (− 0.2 < r < 0.2); Blue = Low to moderate inverse correlation (− 0.5 < r < − 0.2); Red = Low to moderate correlation (0.2 < r < 0.5) (PDF 55 KB)

415_2023_11947_MOESM4_ESM.pdf

Supplementary file4 Scatter plots representing correlations between brain volume changes and clinical changes in PD patients over 1 year. ASBPD = Ardouin Scale of Behavior in Parkinson’s Disease; MDS-UPDRS = Movement Disorder’s Society Unified Parkinson's Disease Rating Scale (PDF 115 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marques, A., Macias, E., Pereira, B. et al. Volumetric changes and clinical trajectories in Parkinson’s disease: a prospective multicentric study. J Neurol 270, 6033–6043 (2023). https://doi.org/10.1007/s00415-023-11947-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-023-11947-0

Keywords

Search

Navigation